What Imbed Biosciences does

Imbed Biosciences Inc. is a privately held medical device company headquartered in Middleton, Wisconsin, founded by physicians and scientists from the University of Wisconsin-Madison. The company develops and commercializes the SAMatrix™ Technology platform — an ultra-thin, fully synthetic, bioresorbable polymeric fiber matrix that integrates antimicrobial silver and (in PainGuard™ variants) lidocaine HCl for combined infection control and non-opioid pain management. Its commercial product family comprises Microlyte® (chronic wounds, including diabetic foot, venous leg, and pressure ulcers), Surgaflex™ (surgical and acute wounds), Pelashield® (burn and acute wounds), and PainGuard™ lidocaine variants of each, supplemented by a veterinary product line. The company has secured FDA 510(k) clearances for the portfolio (including Microlyte Ag/Lidocaine in 2024) and a dedicated CMS HCPCS Level II Code A2040 for Microlyte PainGuard effective April 2026.

Imbed earns revenue through one-time medical device sales of its FDA-cleared wound matrices, distributed primarily through an independent distributor network supplemented by direct sales to enterprise accounts at burn centers, wound centers, hospitals, ASCs, HOPDs, and physician offices. Channel reach is extended via a 2024 GPO agreement with Premier, Inc. and a 2026 strategic investment and distribution partnership with BioLab Holdings targeting physician office and outpatient settings. The GTM motion combines sales-led efforts with channel partners, supported by clinical education through the company-hosted Zero Zone Podcast, clinical webinars, conference participation (ABA, SAWC, Boswick, regional burn conferences), and provider/patient testimonials. Pricing is not publicly disclosed; quotes go through distributors or direct contact.

The company has raised approximately $22M+ since founding across multiple small rounds, an $800K NIH SBIR/NIAMS grant in 2021, a $10M Niterra-led convertible note in January 2024, and an undisclosed BioLab Holdings strategic investment in early 2026. Headcount is in the 11-50 range, consistent with an early-commercial-stage medical device company that is operating, actively executing on its regulatory and reimbursement roadmap, and currently concentrated on U.S. commercialization.

Name

Imbed Biosciences

Legal name

Imbed Biosciences Inc.

Website

https://imbedbio.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Imbed Biosciences is a privately held medical device company that develops and sells the SAMatrix™ Technology platform — FDA-cleared synthetic antimicrobial wound matrices (Microlyte®, Surgaflex™, Pelashield® and PainGuard™ lidocaine variants) — to U.S. burn centers, wound centers, hospitals, ASCs, HOPDs, and physician offices via distributors and direct sales.

Ownership category

akta.pro rank

Product category

Advanced Wound Care Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA), Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips) (HLAHALAD)

Keywords

• Antimicrobial wound matrix
• Synthetic skin substitute
• Advanced wound care
• Burn care dressings
• Surgical wound management

Headquarters

HQ city

Fitchburg

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Wound Care Product Sales: Imbed Biosciences generates revenue through the sale of FDA-cleared antimicrobial wound matrix products including Microlyte®, Surgaflex™, Pelashield®, and their PainGuard™ variants with lidocaine. Products are sold through a distributor network to healthcare facilities including burn centers, wound centers, hospitals, physician offices, ASCs, and HOPDs.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Imbed Biosciences develops and sells FDA-cleared, fully synthetic antimicrobial wound matrices under its proprietary SAMatrix™ Technology platform. The product portfolio includes Microlyte® for chronic wounds, Surgaflex™ for surgical wounds, and Pelashield® for burn and acute wounds, with PainGuard™ variants adding lidocaine HCl for localized non-opioid pain management. Products are sold to healthcare facilities including burn centers, wound centers, hospitals, physician offices, ASCs, and HOPDs through independent distributors.

Product overview

Imbed Biosciences offers a portfolio of synthetic antimicrobial wound matrices under the SAMatrix™ Technology platform. The product family includes Microlyte® (for chronic wounds), Surgaflex™ (for surgical wounds), and Pelashield® (for burn and acute wounds), with antimicrobial silver integrated into each matrix. The portfolio also includes PainGuard variants (Microlyte® PainGuard™, Surgaflex™ PainGuard™, and Pelashield® PainGuard™) that additionally incorporate lidocaine HCl to manage pain along with bioburden reduction. These brands are indicated across a wide range of chronic and acute wounds, including ulcers, surgical, traumatic, and burn wounds.

Differentiator

Problem solved

Functional benefit

Brands

• SAMatrix™ Technology: The company's platform technology integrating multiple wound care agents into an ultra-thin, fully synthetic matrix composed of bioresorbable fibers.
• Microlyte®
• Surgaflex™
• Pelashield®
• PainGuard™

Products and services

• Microlyte®
• Surgaflex™
• Pelashield®
• Microlyte® PainGuard™
• Surgaflex™ PainGuard™
• Pelashield® PainGuard™
• Microlyte® VET

Quantifiable outcome

• Sustained antimicrobial activity for up to 3 days demonstrated against broad spectrum of microbes
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Premier, Inc.coreChannel Partner/ Reseller/ Distributor · 1 February 2024Imbed Biosciences was awarded a Skin Integrity and Wound Care agreement with Premier, Inc., a healthcare improvement company. This GPO agreement provides Premier members access to Imbed's wound care products, facilitating purchasing through Premier's network.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Smith+Nephew: Global medical device leader with a sizable Advanced Wound Management portfolio (e.g., ALLEVYN, PICO). Directly comparable to Imbed as a competitor in advanced wound dressings and antimicrobial matrices across the same hospital, ASC, and outpatient channels.
• Solventum (formerly 3M Health Care): Major wound care and skin health franchise covering advanced dressings, negative pressure wound therapy, and skin integrity solutions. Competes head-to-head with Imbed in antimicrobial and advanced wound dressings across U.S. hospitals and outpatient settings.
• ConvaTec: Specialist in advanced wound care, ostomy, and continence care with AQUACEL and Foam dressing lines. Highly comparable in distribution channels (HOPDs, wound centers, ASCs) and product overlap with Imbed's Microlyte and Surgaflex matrices.
• Mölnlycke Health Care: Global wound care and surgical solutions company with Mepilex, Mepitel, and other advanced dressings used in burn and surgical wound care. Directly competes with Imbed's Pelashield and Surgaflex lines in burn centers and OR settings.
• Coloplast: Danish med-tech with a sizable wound and skin care business (Biatain, Comfeel). Comparable to Imbed in advanced wound dressings for chronic wounds (DFUs, VLUs, pressure ulcers) sold through similar outpatient and home care channels.

Direct peers

• Organogenesis: Regenerative medicine company specializing in advanced wound care and skin substitutes (Apligraf, Dermagraft, PuraPly). Closely comparable to Imbed as a U.S. skin-substitute and chronic-wound competitor selling under similar HCPCS reimbursement pathways.
• MiMedx: Regenerative wound care and surgical recovery company using placental tissue allografts (EpiFix, AmnioFix). Direct competitor to Imbed in the U.S. skin substitute market with similar outpatient and HOPD customer base.
• Integra LifeSciences: Specialty med-tech focused on regenerative tissue technologies and wound care (Integra Dermal Regeneration Template, PriMatrix). Comparable to Imbed in surgical and burn wound matrix technology and hospital channel sales.
• Healthpoint Biotherapeutics (Smith+Nephew): Biotherapeutic wound care franchise (now part of Smith+Nephew) focused on enzymatic debridement and bioactive wound therapies such as Santyl. Comparable to Imbed as a specialized wound-care product company now operating within a major incumbent.

Others

• Cardinal Health: Major U.S. medical products distributor supplying hospitals, ASCs, and physician offices. Relevant ecosystem participant for Imbed because it represents a potential distributor channel and competes indirectly for wound care formulary space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/imbedbio
• LinkedInlinkedin.com/company/3805020

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds13 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imbed Biosciences